Video Experimental Relacionado
Updated: Jul 22, 2026
06:58
Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement
Published on: June 25, 2016
Tratamiento antiepiléptico inmediato versus diferido para la epilepsia temprana y las convulsiones únicas: un ensayo
Lancet (London, England)
|June 14, 2005
Resumen
Comenzar el tratamiento con medicamentos antiepilépticos rápidamente reduce la recurrencia de las convulsiones a corto plazo en pacientes con pocas convulsiones. Sin embargo, el tratamiento inmediato no mejora las tasas de remisión de convulsiones a largo plazo en comparación con el tratamiento retrasado.
Área de la Ciencia:
- Neurología Neurología.
- Farmacología clínica Farmacología clínica.
Sus antecedentes:
- El momento óptimo para iniciar el tratamiento con fármacos antiepilépticos (AED) en pacientes que experimentan convulsiones pocas o infrecuentes sigue siendo incierto.
- Los riesgos y beneficios comparativos de la terapia inmediata versus diferida con DEA requieren una aclaración.
Objetivo del estudio:
- Para comparar las políticas de tratamiento inmediato versus diferido de DEA en pacientes con convulsiones únicas y epilepsia temprana.
- Evaluar el impacto de estas políticas en la recurrencia de las convulsiones a corto plazo y los resultados a largo plazo.
Principales métodos:
- Un estudio desenmascarado, multicéntrico y aleatorizado que involucró a 1847 pacientes con convulsiones únicas o epilepsia temprana.
- Los resultados evaluados incluyeron el tiempo hasta la primera, segunda y quinta convulsiones, el tiempo hasta la remisión de 2 años, la libertad de convulsiones entre los años 1-3 y 3-5 después de la aleatorización y la calidad de vida.
- Se empleó el análisis de intención de tratar.
Principales resultados:
- El tratamiento inmediato con DEA aumentó significativamente el tiempo hasta la primera convulsión (HR 1.4), la segunda convulsión (HR 1.3), y la primera convulsión tónico-clónica (HR 1.5).
- El tratamiento inmediato también aceleró el logro de la remisión de las convulsiones de 2 años (p = 0,023).
- No se observaron diferencias significativas en la ausencia de convulsiones a largo plazo (3-5 años) o en la calidad de vida entre los grupos de tratamiento inmediato y diferido.
Conclusiones:
- El tratamiento inmediato con DEA reduce efectivamente la ocurrencia de las convulsiones en los primeros 1-2 años después de una primera convulsión o diagnóstico de epilepsia temprana.
- La elección entre el tratamiento inmediato y diferido con DEA no parece influir en las tasas de remisión de convulsiones a largo plazo en esta población de pacientes.
Más Videos Relacionados
10:22Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
Published on: December 6, 2016
07:01Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
Videos de Conceptos Relacionados
01:24Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:08Antiepileptic Drugs: Sodium Channel Blockers
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...